295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas

• Hui Zhou,
• Ying Liu,
• Fang Liu,
• Siqing Fu,
• Nehal Lakhani,
• Marlana Orloff,
• Kedan Lin,
• Shuling Yan

Affiliations

Hui Zhou

The Third Clinical Medical College, Zhejiang Chinese Medical University, Department of Neurobiology and Acupuncture Research, Hangzhou, China

Ying Liu

2 Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, USA

Fang Liu

Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

Siqing Fu

Aff3 grid.240145.60000000122914776University of Texas M.D. Anderson Cancer Center Houston TX USA

Nehal Lakhani

4START Midwest, Grand Rapids, MI, USA

Marlana Orloff

2Thomas Jefferson University (Sarah Cannon), Philadelphia, PA, USA

Kedan Lin

4Innovent Biologics, Inc., Shanghai, China

Shuling Yan

4Innovent Biologics, Inc., Shanghai, China